Jump to content

Arrow declaration

From Wikipedia, the free encyclopedia

In UK patent litigation, an Arrow declaration is a declaration or order sought, for reasons of legal certainty, from a court that a product (or process) to be launched was old (i.e., not novel) or obvious in patent law terms at a particular date, so that the product (or process) cannot be affected by (i.e., cannot infringe) any later granted patent, which would itself necessarily also either lack novelty or inventive step.[1][2][3][4] The order is named after Arrow Generics Ltd. v Merck & Co Inc [2007] EWHC 1900 (Pat), in which it was originally suggested that this mechanism would be available as a declaratory relief.[1][3][5] Such a declaration was granted for the first time in Fujifilm Kyowa Kirin Biologics Company Ltd v Abbvie Biotechnology Ltd [2017] EWHC 395 (Pat), Patents Court, England, 3 March 2017.[5]

The defense is similar to a so-called "Gillette defense", i.e. "the argument in infringement proceedings (...) that the defendant's product implements prior art technology, such that any patent which it infringes must be invalid."[1]

See also

[edit]

References

[edit]
  1. ^ a b c Brazell, Lorna (1 September 2017). "Pre-emptive product patentability declarations". Pharmaceutical Patent Analyst. 6 (5): 197–200. doi:10.4155/ppa-2017-0023. ISSN 2046-8954. PMID 28818023.
  2. ^ Adair, Dominic (1 July 2018). "Arrow declarations: here to stay or a flash in the pan?". Pharmaceutical Patent Analyst. 7 (4): 133–136. doi:10.4155/ppa-2018-0009. ISSN 2046-8954. PMID 29882713. S2CID 46983781.
  3. ^ a b England, Paul (November 2019). "Arrow declarations: a creative new remedy, but what are its limits?". Pharmaceutical Patent Analyst. 8 (6): 217–219. doi:10.4155/ppa-2019-0024. PMID 31718455. S2CID 207963034.
  4. ^ Gilbert, Penny; Kendall-Windless, Carissa; Rowlatt, Benjamin (2020). "Will Arrow Relief Take Flight?". Managing Intellectual Property. 286: 45.
  5. ^ a b Daniels, Mark; Parsons, Giles (1 August 2017). "Patents Court grants declarations that dosage regimens were obvious". Journal of Intellectual Property Law & Practice. 12 (8): 624–626. doi:10.1093/jiplp/jpx112. ISSN 1747-1532.

Further reading

[edit]